Grace Therapeutics, Inc. (GRCE) stock

GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31

Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30

$1.81−0.04 (-2.43%)

Close on Nov 12, 2026Market cap $38.08MP/E –Yield –

Grace Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Grace Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?